Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences reported strong Q1 2023 results, with sales of $1.46 billion, a 9% increase year-over-year. TAVR sales reached $948 million, growing 8%, while adjusted EPS was $0.62. The company repurchased $250 million of its stock and raised its full-year sales guidance to a growth of 10-12%. The SAPIEN 3 Ultra RESILIA valve was launched in Japan, and the company completed enrollment for pivotal trials. Q1 gross profit margin was 77.5%, and free cash flow was $253 million. For Q2 2023, sales are projected between $1.48 and $1.56 billion, with adjusted EPS from $0.62 to $0.68.

Edwards Lifesciences (NYSE: EW) will announce its operating results for Q1 2023 on April 26, 2023, after market close. The company will hold a conference call at 5:00 p.m. ET on the same day to discuss these results in detail. Investors can join the call by dialing (877) 704-2848 or (201) 389-0893, with an option to access the live and archived version on the company's Investor Relations website.

As a leading innovator in structural heart disease and critical care monitoring, Edwards Lifesciences focuses on enhancing patient outcomes through collaboration with healthcare professionals.

Edwards Lifesciences (NYSE: EW) presented new data at ACC.23/WCC regarding early-stage aortic stenosis (AS) mortality rates and 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using Medicare data. The study analyzed over 1.6 million echocardiograms, finding a 20% mean 2-year all-cause mortality for moderate untreated AS. Additionally, only 1.63% of 230,644 TAVR patients required re-intervention within ten years. These findings emphasize the need for earlier intervention in AS and suggest decreasing re-intervention rates thanks to advanced technologies.

Edwards Lifesciences reported Q4 2022 sales of $1.35 billion, a 1% increase, with constant currency sales up 7%. TAVR sales remained flat at $868 million. The company reported a Q4 EPS of $0.65 and an adjusted EPS of $0.64, up 25%. For the full year, sales reached $5.38 billion, growing 3% year-over-year. Notably, Edwards repurchased $1.7 billion of its shares in 2022. The company maintains a positive outlook for 2023, with projected sales growth of 9% to 12% and adjusted EPS of $2.45 to $2.60.

Edwards Lifesciences (NYSE: EW) will release its operating results for the quarter ending December 31, 2022, after market close on January 31, 2023. The company will hold a conference call at 5:00 p.m. ET on the same day to discuss these results. Participants can join the call by dialing (877) 704-2848 or (201) 389-0893. The call will also be accessible live and archived on the Investor Relations section of the Edwards website. Edwards Lifesciences is known for its innovations in structural heart disease and critical care monitoring.

Edwards Lifesciences Corporation (NYSE: EW) will participate in the upcoming J.P. Morgan Healthcare Conference on January 10, 2023. The presentation is scheduled for 11:15 a.m. PT and will be led by CEO Michael A. Mussallem, alongside Bernard Zovighian and CFO Scott Ullem. A live webcast will be available on the Edwards Lifesciences investor relations website, with an archived version accessible later that day. Edwards Lifesciences is recognized for its innovations in structural heart disease and critical care monitoring.

Edwards Lifesciences Corporation (NYSE: EW) presented its long-term growth strategy, technology pipeline updates, and financial guidance during its annual investor conference on December 8, 2022. Key highlights include a projected global market opportunity nearing $20 billion by 2028 and reaffirmation of October 2022 financial guidance. For 2023, sales are expected between $5.6 billion and $6.0 billion, with 9%-12% underlying growth. TAVR sales are projected at $3.6 billion to $4.0 billion. The company also plans to invest 17%-18% of sales in R&D to drive innovations.

Edwards Lifesciences Corporation (NYSE: EW) announced its CEO succession plan due to Michael A. Mussallem's upcoming retirement at the Annual Meeting of Stockholders on May 11, 2023. Bernard Zovighian, currently the vice president and general manager of the Transcatheter Mitral and Tricuspid Therapies (TMTT) business, will become CEO after serving as president starting January 1, 2023. Larry Wood and Daveen Chopra are also assuming expanded roles. The company emphasizes a smooth transition and its commitment to patient-focused innovation in the medical field.

Edwards Lifesciences Corporation (NYSE: EW) reported promising one-year results from the TRISCEND study of its EVOQUE transcatheter tricuspid valve replacement system. The study involved 176 patients with symptomatic tricuspid regurgitation. Key outcomes include a 90.1% survival rate and 88.4% freedom from heart failure hospitalization. Additionally, 97.6% of patients experienced significant TR reduction. The results highlight the EVOQUE system's potential as a vital treatment option for patients with this condition, emphasizing Edwards' commitment to innovative therapies.